Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532124 | 1.00 | EPHX2 (0.53) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL796858 | 1.00 | EPHX2 (0.53) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL5271411 | 0.90 | EPHX2 (0.59) | EPHX2SRD5A1SCD5CYP2C9CYP2J2 | |
| SCHEMBL594896 | 0.87 | SRD5A1 (0.45) | EPHX2SRD5A1USP30 | |
| SCHEMBL6123598 | 0.87 | EPHX2 (0.51) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL10606119 | 0.87 | EPHX2 (0.54) | EPHX2SRD5A1SCD5RIPK1USP30 | |
| SCHEMBL594897 | 0.87 | SRD5A1 (0.45) | EPHX2SRD5A1USP30 | |
| SCHEMBL12442639 | 0.86 | NAMPT (0.57) | EPHX2SRD5A1SCD5RIPK1 | |
| SCHEMBL29067466 | 0.86 | POLB (0.47) | EPHX2SRD5A1GAACYP2C9 | |
| SCHEMBL29132289 | 0.86 | EPHX2 (0.54) | EPHX2CYP2C9CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8486992-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8268881-B2 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2011-10-13 | — | — | US | disclosed |
| US-7772223-B2 | 5-Methyl-5-(3-phenoxyazetidin-1-yl)-2,2-diphenylhexanamide, used for the treatment of respiratory system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis and emphysema | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-02-04 | — | — | US | disclosed |
| EP-1928821-B1 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | EPHX2 1549/4885SRD5A1 392/4885SCD5 1829/4885 |
| US-20110251164-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | EPHX2 1013/4885SRD5A1 1435/4885SCD5 975/4885 |
| US-20070105831-A1 | Carboxamide derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | EPHX2 1013/4885SRD5A1 1435/4885SCD5 975/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | EPHX2 1549/4885SRD5A1 392/4885SCD5 1829/4885 |
| US-20100029720-A1 | Carboxamide Derivatives As Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | EPHX2 1013/4885SRD5A1 1435/4885SCD5 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.